



September 30, 2022

Dear Lantheus Customer,

In March of this year, we announced our decision to discontinue production of Thallium-201 and Gallium-67 in late 2022. We are now ending production of these two products. We believe that there are other choices in the market, including other modalities, to avoid detrimental effect on patients, and hope that the notice we provided to you earlier this year has allowed time for you to plan with your customers.

Lantheus has been instrumental in pioneering the nuclear medicine industry. Building on more than 65 years of life-changing science, we continue to innovate to deliver on what matters for healthcare professionals and patients. While we are halting production of Thallium-201 and Gallium-67, we continue to offer a broad product portfolio of both imaging and therapeutic products that enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Our broad portfolio includes innovative products like PYLARIFY® and AZEDRA®; TechnoLite®, the most reliable Tc-99m generator in the industry; as well as Xenon-133, NEUROLITE®, and Cardiolite®.

Should you have any questions or need additional information, please contact your Lantheus Nuclear Medicine Account Director or call Lantheus Customer Service at 1-800-299-3431.

Sincerely,

A handwritten signature in black ink, appearing to read 'John Wiggins', with a stylized flourish at the end.

John Wiggins
Vice President, Isotope Strategy and SPECT Franchise